{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T21:35:50Z","timestamp":1785706550760,"version":"3.56.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1053\/j.seminhematol.2012.04.010","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T05:09:40Z","timestamp":1340168980000},"page":"228-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Bortezomib Combination Therapy in Multiple Myeloma"],"prefix":"10.1053","volume":"49","author":[{"given":"Prashant","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.04.010_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib2","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib4","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib5","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cncr.21740","article-title":"Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial","volume":"106","author":"Richardson","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib7","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to proteasome inhibitor bortezomib is correlated with unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"15S","key":"10.1053\/j.seminhematol.2012.04.010_bib10","first-page":"8536","article-title":"Lenalidomide, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study","volume":"27","author":"Anderson","year":"2009","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib11","article-title":"Randomized, multicenter phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide and lenalidomide in previously untreated multiple myeloma","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib13","first-page":"130","article-title":"Thalidomide\/dexamethasone (TD) vs. bortezomib (Velcade)a\/thalidomide\/dexamethasone (VTD) vs. VBMCP\/VBAD\/Velcadea as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA\/GEM trial","volume":"114","author":"Rosinol","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib14","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.seminhematol.2012.04.010_bib17","first-page":"476","volume":"118","author":"Miguel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib18","first-page":"2933","article-title":"Risk of second primary malignancies (SPMs) following bortezomib (Btz)-based therapy: analysis of four phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (MM)","volume":"118","author":"Miguel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib20","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib22","first-page":"478","article-title":"Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib23","first-page":"1864","article-title":"Patient-reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study","volume":"118","author":"Niesvizky","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib24","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib25","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib26","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2008.07147.x","article-title":"The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma","volume":"141","author":"Ciolli","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2011.08884.x","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients","volume":"155","author":"Berenson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib29","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib31","first-page":"40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM)","volume":"116","author":"Sonneveld","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib32","first-page":"653","article-title":"First analysis of HOVON-65\/GMMG-HD4 randomized phase III Trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)","volume":"112","author":"Sonneveld","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","article-title":"Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2","volume":"140","author":"Pineda-Roman","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib35","first-page":"1342","article-title":"Prognostic index for predicting overall survival and event-free survival in Total Therapy 3 patients","volume":"116","author":"Hoering","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib36","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib37","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2011.08664.x","article-title":"Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1\/2 study","volume":"153","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2010-04-278507","article-title":"Proteasome and HDAC: who's zooming who?","volume":"116","author":"McConkey","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib41","first-page":"814","article-title":"Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2)","volume":"118","author":"Richardson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib42","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"issue":"s1","key":"10.1053\/j.seminhematol.2012.04.010_bib43","first-page":"S94","article-title":"Vorinostat overcomes resistance in patients with multiple myeloma refractory to bortezomib, lenalidonide and dexamethasone","volume":"96","author":"Siegel","year":"2011","journal-title":"Hematologica"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib44","first-page":"811","article-title":"Vantage 088: vorinostat in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: results of a global, randomized phase 3 trial","volume":"118","author":"Dimopoulos","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib45","first-page":"3976","article-title":"Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1","volume":"118","author":"San-Miguel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2011.37.9701","article-title":"From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin","volume":"30","author":"Hidalgo","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib47","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1182\/blood-2011-03-342394","article-title":"Defining the role of TORC1\/2 in multiple myeloma","volume":"118","author":"Maiso","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1470-2045(11)70028-6","article-title":"Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1\/2, open-label, dose-escalation study","volume":"12","author":"Ghobrial","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib49","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells","volume":"107","author":"Hideshima","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib50","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":"Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I\/II trial","volume":"29","author":"Richardson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib51","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2003-08-2764","article-title":"Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma","volume":"103","author":"Alsina","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib52","first-page":"3706","article-title":"A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed\/refractory multiple myeloma","volume":"112","author":"Lonial","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2011.08790.x","article-title":"Monoclonal antibodies in the treatment of multiple myeloma","volume":"154","author":"Richardson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib54","first-page":"5031","article-title":"A multicenter randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma (MM)","volume":"116","author":"Belch","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib55","first-page":"3023","article-title":"Elotuzumab in combination with bortezomib in patients with relapsed\/refractory multiple myeloma: updated results of a phase I study","volume":"116","author":"Jakubowiak","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase I results from the multicenter EVOLUTION study","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib57","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2011-02-334755","article-title":"Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1\/2 Multiple Myeloma Research Consortium trial","volume":"118","author":"Jakubowiak","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib58","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-009-0726-6","article-title":"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib\/dexamethasone for remission induction in patients with newly diagnosed myeloma","volume":"88","author":"Kropff","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.2011.08703.x","article-title":"A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients","volume":"154","author":"Sher","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib60","first-page":"3618","article-title":"Bortezomib [VELCADE], pegylated liposomal doxorubicin [DOXIL\/CAELYX] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life","volume":"110","author":"Belch","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib61","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib63","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","article-title":"Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma","volume":"19","author":"Palumbo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib64","first-page":"1857","article-title":"Bendamustine combined with bortezomib has efficacy in patients with relapsed or refractory multiple myeloma: a phase 1\/2 study","volume":"118","author":"Berenson","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib65","first-page":"480","article-title":"Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial","volume":"118","author":"Siegel","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib66","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ajh.22048","article-title":"A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma","volume":"86","author":"Ghobrial","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.04.010_bib67","first-page":"867","article-title":"Preliminary Results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma","volume":"112","author":"Rossi","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"S1","key":"10.1053\/j.seminhematol.2012.04.010_bib68","first-page":"S69","article-title":"Results of pre- and post- autologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib (VBMCP\/VBAD\/V)","volume":"96","author":"Rosinol","year":"2011","journal-title":"Hematologica"},{"issue":"s1","key":"10.1053\/j.seminhematol.2012.04.010_bib69","first-page":"S72","article-title":"Bortezomib (Velcade)-thalidomide-dexaemthasone (VTD) is superior to thalidomide-dexaemthasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation","volume":"96","author":"Garderet","year":"2011","journal-title":"Hematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:50Z","timestamp":1758522050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0037196312000339"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib Combination Therapy in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}